High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

BACKGROUND. In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary endocrine treatment efficacy, but its value as a predictor of response to chemotherapy is still controversial. PATIENTS AND METHODS. We analyzed 262 patients with centralized basal Ki67 immun...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Alba, Emilio, Lluch, Ana, Ribelles, Nuria, Anton-Torres, Antonio, Sanchez-Rovira, Pedro, Albanell, Joan, Calvo, Lourdes, García-Asenjo, Jose Antonio Lopez, Palacios, Jose, Chacon, Jose Ignacio, Ruiz, Amparo, De la Haba-Rodriguez, Juan, Segui-Palmer, Miguel A., Cirauqui, Beatriz, Margeli, Mireia, Plazaola, Arrate, Barnadas, Agusti, Casas, Maribel, Caballero, Rosalia, Carrasco, Eva, Rojo, Federico
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2016
Témata:
Breast Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4746087/
https://ncbi.nlm.nih.gov/pubmed/26786263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0312
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky